Dashboard
Manage Tickers

ATOSATOSSA THERAPEUTICS, INC.

Nasdaq atossatherapeutics.com


$ 1.36 $ 0.03 (2.26 %)    

Monday, 09-Sep-2024 15:59:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.36
$ 1.35 x 1,000
$ 1.36 x 1,699
-- - --
$ 0.62 - $ 2.31
470,250
na
171.03M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-13-2019 03-31-2019 10-Q
23 03-28-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-14-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-11-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-12-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-13-2015 03-31-2015 10-Q
39 03-30-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atossa-therapeutics-granted-new-patent-directed-to-compositions-comprising-endoxifen-and-an-anteric-material-in-which-at-least-90-of-the-endoxifen-is-z-endoxifen
Atossa Therapeutics Granted New Patent Dir...
08/28/2024 12:33:34

atossa-therapeutics-and-quantum-leap-healthcare-collaborative-dose-first-patient-in-clinical-trial-evaluating-z-endoxifen-with-abemaciclib-as-neoadjuvant-treatment-for-high-risk-erher2--breast-cancer
Atossa Therapeutics And Quantum Leap Healt...
08/21/2024 12:30:51

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
08/12/2024 17:53:30

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $6 price ...

atossa-therapeutics-q2-eps-005-beats-006-estimate
Atossa Therapeutics Q2 EPS $(0.05) Beats $...
08/12/2024 12:36:53

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-completes-enrollment-of-80mg-pharmacokinetic-run-in-cohort-in-phase-2-evangeline-clinical-trial-evaluating-z-endoxifen-for-er--her2--breast-cancer
Atossa Therapeutics Completes Enrollment O...
07/22/2024 12:33:45

atossa-therapeutics-appoints-heather-rees-as-new-cfo
Atossa Therapeutics Appoints Heather Rees ...
07/02/2024 20:16:04

Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. 

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
06/28/2024 15:12:47

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $6 price ...

atossa-therapeutics-announces-updated-protocol-for-clinical-trial-evaluating-z-endoxifen-in-combination-with-abemaciclib-in-women-with-erher2--breast-cancer
Atossa Therapeutics Announces Updated Prot...
06/28/2024 12:36:28

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced protocol changes in the pre...

cantor-fitzgerald-reiterates-overweight-on-atossa-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:26:50

Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Overweight.

atossa-to-join-russell-3000-index
Atossa To Join Russell 3000 Index
06/17/2024 12:34:29

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-625
Ascendiant Capital Maintains Buy on Atossa...
06/06/2024 17:07:25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-last-patient-its-phase-2-karisma-endoxifen-clinical-trial-recieved-their-final-dose
Atossa Therapeutics Last Patient Its Phase...
05/15/2024 12:39:30

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the last patient in th...

cantor-fitzgerald-reiterates-overweight-on-atossa-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 13:25:09

Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Overweight.

hc-wainwright--co-maintains-buy-on-atossa-therapeutics-raises-price-target-to-6
HC Wainwright & Co. Maintains Buy on Atoss...
05/13/2024 16:54:59

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price tar...

atossa-therapeutics-q1-2024-adj-eps-005-beats-007-estimate
Atossa Therapeutics Q1 2024 Adj EPS $(0.05...
05/13/2024 12:54:22

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-announces-support-of-new-breast-cancer-screening-guidelines
Atossa Therapeutics Announces Support Of N...
05/07/2024 12:46:50

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelin...

atossa-therapeutics-announces-expanded-research-agreement-with-weill-cornell-medicine-to-further-evaluate-synergy-between-antibody-drug-conjugates-and-z-endoxifen
Atossa Therapeutics Announces Expanded Res...
04/29/2024 12:34:28

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreem...

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
04/16/2024 15:01:19

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $4 price ...

atossa-therapeutics-and-quantum-leap-healthcare-initiates-i-spy-2-clinical-trial-to-evaluate-z-endoxifen-in-combination-with-abemaciclib-in-women-with-erher2--breast-cancer
Atossa Therapeutics And Quantum Leap Healt...
04/15/2024 12:39:34

The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Gr...

atossa-therapeutics-presents-data-from-40mg-cohort-of-phase-2-evangeline-clinical-trial
Atossa Therapeutics Presents Data From 40m...
04/09/2024 16:00:06

The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION